Momenta Phama (MNTA) Misses Q2 EPS by 50c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Momenta Phama (MNTA) Misses Q2 EPS by 50c, Revenues Miss

Momenta Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update

August 9, 2018 6:00 AM EDT

CAMBRIDGE, Mass., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today reported its financial results for the second quarter ended June 30, 2018 and provided a corporate update.

The strategic review of our business announced earlier this year is progressing and we are actively evaluating options for our biosimilars business. We expect to complete this review and announce an outcome in the coming weeks, said Craig A. Wheeler, President and Chief Executive Officer of Momenta Pharmaceuticals. Our novel drug candidates for rare autoimmune diseases continue to advance. We remain on track to... More